Nervous System News and Research

Latest Nervous System News and Research

AB Science announces results from masitinib phase 2 study on MS

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis.

14 Jun 2012

New analogues effective in inhibiting NOS activity in Parkinson models

University of Granada researchers have tested melatonin analogues in rats as it inhibits the enzyme nitric oxide synthase (NOS), which is involved in the development of conditions as inflammatory bowel disease, septic shock or rheumatoid arthritis, as well as in neurodegenerative conditions as Huntington's disease, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

14 Jun 2012

EnVivo to present results from EVP-6124 Phase 2b trial on AD at AAIC 2012

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that the company will present a comprehensive analysis of its recently completed Phase 2b clinical trial of EVP-6124 in Alzheimer's disease at the Alzheimer's Association International Conference 2012 (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia.

14 Jun 2012

New combination therapy can help improve cure rates for neuroblastoma

An experimental treatment that combines intense chemotherapy with a radioactive isotope linked to synthesized neurotransmitter is being tested in newly diagnosed cases of high-risk neuroblastoma - a deadly, hard-to-cure childhood cancer.

13 Jun 2012

Controlled blood sugar in diabetes can prevent painful nerves: but at what cost?

Aggressive control of blood sugar levels in diabetes can help to prevent a painful condition affecting patients’ nerves, according to a new systematic review in The Cochrane Library. However, the review suggests that optimal target levels need to be established to prevent serious complications.

13 Jun 2012

Omega-3 probably does not reduce cognitive decline in older people

Older people who take omega-3 fish oil supplements are probably not reducing their chances of losing cognitive function, according to a new Cochrane systematic review.

13 Jun 2012

Gut microbes regulate brain levels of serotonin

UCC scientists have shown that brain levels of serotonin, the 'happy hormone' are regulated by the amount of bacteria in the gut during early life. Their research is being published today in the leading international psychiatry journal, Molecular Psychiatry.

13 Jun 2012

Changes in walking speed in late life may signal MCI

A new study shows that changes in walking speed in late life may signal the early stages of dementia known as mild cognitive impairment (MCI).

12 Jun 2012

Uncertainty over efficacy of clopidogrel in hemolytic uremic syndrome

Clinical outcomes for children hospitalized with diarrhea-associated hemolytic uremic syndrome are comparable between those treated with clopidogrel and those who are not, show study findings.

12 Jun 2012

Updated AAN guideline outlines treatments for infantile spasms

The American Academy of Neurology has issued an updated guideline outlining the best treatments for infantile spasms, a rare type of seizure that can occur in infants and young children.

12 Jun 2012

Mutation responsible for rare, hereditary motor neuron disease disrupts vital links

Studying how nerve cells send and receive messages, Johns Hopkins scientists have discovered new ways that genetic mutations can disrupt functions in neurons and lead to neurodegenerative disease, including amyotrophic lateral sclerosis (ALS).

11 Jun 2012

FDA accepts Avanir IND for AVP-923 to treat agitation in patients with AD

Avanir Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease (AD).

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

UF Proton Therapy Institute successfully treats first eye cancer patient

The fixed beam room, or eyeline, at the University of Florida Proton Therapy Institute is up and running and radiation oncologist Robert Malyapa, M.D., Ph.D. completed treating the facility's first eye cancer patient this week.

10 Jun 2012

What are vitamins?

Most people have heard of vitamin C and its effects upon the body; but how much do you know about other vitamins? How many even are there? And what do they all do?

8 Jun 2012

New study into pain associated with diabetes

Researchers in Sheffield have been awarded over £310,000 to carry out a study that could help revolutionise the way clinicians treat the pain experienced by thousands of people with diabetes.

8 Jun 2012

Paper spotlights unique developmental strategy undertaken by all mammals

Ask the average person the street how the brain develops, and they'll likely tell you that the brain's wiring is built as newborns first begin to experience the world. With more experience, those connections are strengthened, and new branches are built as they learn and grow. A new study conducted in a Harvard lab, however, suggests that just the opposite is true.

7 Jun 2012

People on calorie restriction have better heart rate variability

People who restrict their caloric intake in an effort to live longer have hearts that function more like those in people who are 20 years younger.

7 Jun 2012

Regular meditation could reduce risk of cardiovascular disease among teens

Regular meditation could decrease the risk of developing cardiovascular disease in teens who are most at risk, according to Georgia Health Sciences University researchers.

7 Jun 2012

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

6 Jun 2012